Next Article in Journal
A Recombinant RBD-Based Phage Vaccine Report: A Solution to the Prevention of New Diseases?
Next Article in Special Issue
Long-Term Immunogenicity and Safety of a Homologous Third Dose Booster Vaccination with TURKOVAC: Phase 2 Clinical Study Findings with 32-Week Post-Booster Follow-Up
Previous Article in Journal
Development of MVA-d34 Tetravalent Dengue Vaccine: Design and Immunogenicity
Previous Article in Special Issue
SARS-CoV-2-Neutralizing Antibody Response and Correlation of Two Serological Assays with Microneutralization
 
 
Article

Article Versions Notes

Vaccines 2023, 11(4), 832; https://doi.org/10.3390/vaccines11040832
Action Date Notes Link
article xml file uploaded 12 April 2023 15:46 CEST Original file -
article xml uploaded. 12 April 2023 15:46 CEST Update https://www.mdpi.com/2076-393X/11/4/832/xml
article pdf uploaded. 12 April 2023 15:46 CEST Version of Record https://www.mdpi.com/2076-393X/11/4/832/pdf
article supplementary file uploaded. 12 April 2023 15:46 CEST - https://www.mdpi.com/2076-393X/11/4/832#supplementary
article html file updated 12 April 2023 15:48 CEST Original file -
article supplementary file uploaded. 20 April 2023 04:11 CEST - https://www.mdpi.com/2076-393X/11/4/832#supplementary
article html file updated 20 April 2023 04:12 CEST Update -
article supplementary file uploaded. 20 April 2023 04:14 CEST - https://www.mdpi.com/2076-393X/11/4/832#supplementary
article html file updated 20 April 2023 21:59 CEST Update https://www.mdpi.com/2076-393X/11/4/832/html
Back to TopTop